Which research priorities for AD in 2024? Curative precision medicine vs preventive exposome-targeted medicine. Dear Colleagues, Dear Friends, In a recently published provocative perspective paper (DOI: 10.3389/fpubh.2024.1351732), Ian A. Myles, a NIH researcher, asks some good questions to our community which could help shaping our priorities. Currently, with the industry-led dramatic development of biologics and […]
Read More
Release of the 4th Davos declaration on AD and Allergy➜ DOI: 10.1111/all.16247The 2022 Forum is now published with its usual “Declaration” signed by all participants. Besides the mounting burden of AD, attributed to significant environmental and lifestyle changes, the Forum acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in [...] Read More
#RAJKAMedal Rajka medal and prize: the winner among 7 excellent applicants from originating from China, Japan, Korea and Madagascar, is Dr Fang WANG, MD, PhD, Professor and Chief Physician at Sun Yat-Sen University, Guangzhou, China. Dr WANG has an outstanding CV and list of publications. She is a dermatologist with a strong background in neuroimmunology applied to […]
Read More
#RAJKA2024Doha #RAJKAMedal Dear Colleagues, Dear Friends, The abstract submission to the 14th Georg Rajka Symposium on AD (Doha, Qatar, October 24-26, 2024) closed as scheduled on July 15th. 149 abstracts from 32 countries were received. They are currently adjudicated, and the outcome will be available soon in second half of August. All accepted abstracts will be […]
Read More
Cell therapy for atopic dermatitis➜ DOI: 10.1016/j.jaci.2024.06.021Mesenchymal stem cells (MSCs) have been found to play a role in regulating immune responses. Allogenic human bone marrow-derived clonal MSCs (hcMSCs) were administered intravenously weekly for 3 weeks in volunteers with moderate to severe atopic dermatitis (AD) by Korean investigators, with improvement of objective scores at 12 weeks, with [...] Read More
Migayron et al. Front Immunol➜ DOI: 10.3389/fimmu.2024.1405215Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?This is an interesting review which approaches indirectly some of the paradoxical findings observed using targeted therapies in AD. Silverberg et al JAAD➜ DOI: 10.1016/j.jaad.2024.05.023Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis [...] Read More
What PubMed tell us about current trends in AD research? Dear Colleagues, Dear Friends, Since the approval of dupilumab for severe adult AD by the FDA in 2017, published AD research has been tremendously driven by RCTs and associated research concerning dupilumab and other new systemic/ topical therapies designed to control TH2 inflammation. The influence […]
Read More
The 2024 Rajka Medal and Prize will be attributed, please have a look at the criteria to apply, this year will be very competitive! From 2024, an accompanying prize of 15.000 EUR will be given to the awardee to contribute to further research at his/her institution. In memory of Professor Georg RAJKA and his pioneering […]
Read More
Dear Colleagues, Dear Friends, Our May 2024 newsletter features ISAD collaboration with ILDS on the World Skin Health Day (WSHD) in Guinea and Madagascar, a national program to promote skin health including AD in Mauritania, the opening of the RAJKA2024 Call for Abstracts (ISAD Doha) and a focus on its pre-meeting: Patient-Centered Care in Atopic […]
Read More
Carmanius et al, JEADV 2024➜ DOI: 10.1111/jdv.20076A cross-sectional study based on the 24-year follow-up from the population-based birth cohort linked with dispensing data from the National Swedish Drug Register confirms that a large proportion of young adults with AD is undertreated or untreated. Kook et al, JEADV 2024➜ DOI: 10.1111/jdv.20053Misdiagnosis of AD or confounding skin diseases in [...] Read More